APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

George Lau; Ming Lung Yu; Grace Wong; Alexander Thompson; Hasmik Ghazinian; Jin Lin Hou; Teerha Piratvisuth; Ji Dong Jia; Masashi Mizokami; Gregory Cheng; Guo Feng Chen; Zhen Wen Liu; Oidov Baatarkhuu; Ann Lii Cheng; Woon Leung Ng; Patrick Lau; Tony Mok; Jer Ming Chang; Saeed Hamid; A. Kadir Dokmeci; Rino A. Gani; Diana A. Payawal; Pierce Chow; Joong Won Park; Simone I. Strasser; Rosmawaiti Mohamed; Khin Maung Win; Tanwandee Tawesak; Shiv Kumar Sarin; Masao Omata

doi:10.1007/s12072-021-10239-x

APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

George Lau, Ming Lung Yu, Grace Wong, Alexander Thompson, Hasmik Ghazinian, Jin Lin Hou, Teerha Piratvisuth, Ji Dong Jia, Masashi Mizokami, Gregory Cheng, Guo Feng Chen, Zhen Wen Liu, Oidov Baatarkhuu, Ann Lii Cheng, Woon Leung Ng, Patrick Lau, Tony Mok, Jer Ming Chang, Saeed Hamid, A. Kadir DokmeciRino A. Gani, Diana A. Payawal, Pierce Chow, Joong Won Park, Simone I. Strasser, Rosmawaiti Mohamed, Khin Maung Win, Tanwandee Tawesak, Shiv Kumar Sarin, Masao Omata

Department of Medicine, Medical College, Pakistan

Research output: Contribution to journal › Article › peer-review

82 Citations (Scopus)

Abstract

Background & Aim: Hepatitis B reactivation related to the use of immunosuppressive therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic Asia-Pacific region. This clinical practice guidelines aim to assist clinicians in all disciplines involved in the use of immunosuppressive therapy to effectively prevent and manage hepatitis B reactivation. Methods: All publications related to hepatitis B reactivation with the use of immunosuppressive therapy since 1975 were reviewed. Advice from key opinion leaders in member countries/administrative regions of Asian-Pacific Association for the study of the liver was collected and synchronized. Immunosuppressive therapy was risk-stratified according to its reported rate of hepatitis B reactivation. Recommendations: We recommend the necessity to screen all patients for hepatitis B prior to the initiation of immunosuppressive therapy and to administer pre-emptive nucleos(t)ide analogues to those patients with a substantial risk of hepatitis and acute-on-chronic liver failure due to hepatitis B reactivation.

Original language	English
Pages (from-to)	1031-1048
Number of pages	18
Journal	Hepatology International
Volume	15
Issue number	5
DOIs	https://doi.org/10.1007/s12072-021-10239-x
Publication status	Published - Oct 2021

Keywords

APASL
Guideline
Hepatitis B reactivation
Immunosuppressive therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12072-021-10239-x

Cite this

Lau, G., Yu, M. L., Wong, G., Thompson, A., Ghazinian, H., Hou, J. L., Piratvisuth, T., Jia, J. D., Mizokami, M., Cheng, G., Chen, G. F., Liu, Z. W., Baatarkhuu, O., Cheng, A. L., Ng, W. L., Lau, P., Mok, T., Chang, J. M., Hamid, S., ... Omata, M. (2021). APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatology International, 15(5), 1031-1048. https://doi.org/10.1007/s12072-021-10239-x

@article{ead2b1c9ca6046d1b6a9b04265a11f4f,

title = "APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy",

abstract = "Background & Aim: Hepatitis B reactivation related to the use of immunosuppressive therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic Asia-Pacific region. This clinical practice guidelines aim to assist clinicians in all disciplines involved in the use of immunosuppressive therapy to effectively prevent and manage hepatitis B reactivation. Methods: All publications related to hepatitis B reactivation with the use of immunosuppressive therapy since 1975 were reviewed. Advice from key opinion leaders in member countries/administrative regions of Asian-Pacific Association for the study of the liver was collected and synchronized. Immunosuppressive therapy was risk-stratified according to its reported rate of hepatitis B reactivation. Recommendations: We recommend the necessity to screen all patients for hepatitis B prior to the initiation of immunosuppressive therapy and to administer pre-emptive nucleos(t)ide analogues to those patients with a substantial risk of hepatitis and acute-on-chronic liver failure due to hepatitis B reactivation.",

keywords = "APASL, Guideline, Hepatitis B reactivation, Immunosuppressive therapy",

author = "George Lau and Yu, {Ming Lung} and Grace Wong and Alexander Thompson and Hasmik Ghazinian and Hou, {Jin Lin} and Teerha Piratvisuth and Jia, {Ji Dong} and Masashi Mizokami and Gregory Cheng and Chen, {Guo Feng} and Liu, {Zhen Wen} and Oidov Baatarkhuu and Cheng, {Ann Lii} and Ng, {Woon Leung} and Patrick Lau and Tony Mok and Chang, {Jer Ming} and Saeed Hamid and Dokmeci, {A. Kadir} and Gani, {Rino A.} and Payawal, {Diana A.} and Pierce Chow and Park, {Joong Won} and Strasser, {Simone I.} and Rosmawaiti Mohamed and Win, {Khin Maung} and Tanwandee Tawesak and Sarin, {Shiv Kumar} and Masao Omata",

note = "Publisher Copyright: {\textcopyright} 2021, Asian Pacific Association for the Study of the Liver.",

year = "2021",

month = oct,

doi = "10.1007/s12072-021-10239-x",

language = "English",

volume = "15",

pages = "1031--1048",

journal = "Hepatology International",

issn = "1936-0533",

publisher = "Springer New York",

number = "5",

}

Lau, G, Yu, ML, Wong, G, Thompson, A, Ghazinian, H, Hou, JL, Piratvisuth, T, Jia, JD, Mizokami, M, Cheng, G, Chen, GF, Liu, ZW, Baatarkhuu, O, Cheng, AL, Ng, WL, Lau, P, Mok, T, Chang, JM, Hamid, S, Dokmeci, AK, Gani, RA, Payawal, DA, Chow, P, Park, JW, Strasser, SI, Mohamed, R, Win, KM, Tawesak, T, Sarin, SK & Omata, M 2021, 'APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy', Hepatology International, vol. 15, no. 5, pp. 1031-1048. https://doi.org/10.1007/s12072-021-10239-x

TY - JOUR

T1 - APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

AU - Lau, George

AU - Yu, Ming Lung

AU - Wong, Grace

AU - Thompson, Alexander

AU - Ghazinian, Hasmik

AU - Hou, Jin Lin

AU - Piratvisuth, Teerha

AU - Jia, Ji Dong

AU - Mizokami, Masashi

AU - Cheng, Gregory

AU - Chen, Guo Feng

AU - Liu, Zhen Wen

AU - Baatarkhuu, Oidov

AU - Cheng, Ann Lii

AU - Ng, Woon Leung

AU - Lau, Patrick

AU - Mok, Tony

AU - Chang, Jer Ming

AU - Hamid, Saeed

AU - Dokmeci, A. Kadir

AU - Gani, Rino A.

AU - Payawal, Diana A.

AU - Chow, Pierce

AU - Park, Joong Won

AU - Strasser, Simone I.

AU - Mohamed, Rosmawaiti

AU - Win, Khin Maung

AU - Tawesak, Tanwandee

AU - Sarin, Shiv Kumar

AU - Omata, Masao

PY - 2021/10

Y1 - 2021/10

N2 - Background & Aim: Hepatitis B reactivation related to the use of immunosuppressive therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic Asia-Pacific region. This clinical practice guidelines aim to assist clinicians in all disciplines involved in the use of immunosuppressive therapy to effectively prevent and manage hepatitis B reactivation. Methods: All publications related to hepatitis B reactivation with the use of immunosuppressive therapy since 1975 were reviewed. Advice from key opinion leaders in member countries/administrative regions of Asian-Pacific Association for the study of the liver was collected and synchronized. Immunosuppressive therapy was risk-stratified according to its reported rate of hepatitis B reactivation. Recommendations: We recommend the necessity to screen all patients for hepatitis B prior to the initiation of immunosuppressive therapy and to administer pre-emptive nucleos(t)ide analogues to those patients with a substantial risk of hepatitis and acute-on-chronic liver failure due to hepatitis B reactivation.

AB - Background & Aim: Hepatitis B reactivation related to the use of immunosuppressive therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic Asia-Pacific region. This clinical practice guidelines aim to assist clinicians in all disciplines involved in the use of immunosuppressive therapy to effectively prevent and manage hepatitis B reactivation. Methods: All publications related to hepatitis B reactivation with the use of immunosuppressive therapy since 1975 were reviewed. Advice from key opinion leaders in member countries/administrative regions of Asian-Pacific Association for the study of the liver was collected and synchronized. Immunosuppressive therapy was risk-stratified according to its reported rate of hepatitis B reactivation. Recommendations: We recommend the necessity to screen all patients for hepatitis B prior to the initiation of immunosuppressive therapy and to administer pre-emptive nucleos(t)ide analogues to those patients with a substantial risk of hepatitis and acute-on-chronic liver failure due to hepatitis B reactivation.

KW - APASL

KW - Guideline

KW - Hepatitis B reactivation

KW - Immunosuppressive therapy

UR - http://www.scopus.com/inward/record.url?scp=85113351403&partnerID=8YFLogxK

U2 - 10.1007/s12072-021-10239-x

DO - 10.1007/s12072-021-10239-x

M3 - Article

C2 - 34427860

AN - SCOPUS:85113351403

SN - 1936-0533

VL - 15

SP - 1031

EP - 1048

JO - Hepatology International

JF - Hepatology International

IS - 5

ER -

APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this